US equities
|
INTC
$64.74
▼-29.68%
AMZN
$238.66
▼-2.10%
MU
$881.18
▼-5.68%
NVDA
$205.39
▼-3.87%
SNDK
$1,168.70
▼-12.13%
GOOGL
$281.94
▼-0.66%
SPCX
$138.28
▼-3.90%
TSLA
$400.15
▼-0.78%
INTC
$64.74
▼-29.68%
AMZN
$238.66
▼-2.10%
MU
$881.18
▼-5.68%
NVDA
$205.39
▼-3.87%
SNDK
$1,168.70
▼-12.13%
GOOGL
$281.94
▼-0.66%
SPCX
$138.28
▼-3.90%
TSLA
$400.15
▼-0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Dermata Therapeutics, Inc. - Warrant
(NQ:
DRMAW
)
0.0006
UNCHANGED
Last Price
Updated: 12:15 PM EDT, Aug 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dermata Therapeutics, Inc. - Warrant
< Previous
1
2
3
Next >
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 03, 2024
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 13, 2024
Via
ACCESSWIRE
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
November 11, 2024
– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com –
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
October 08, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
September 17, 2024
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 07, 2024
Via
ACCESSWIRE
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
July 17, 2024
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
September 16, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
September 05, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
May 17, 2024
Via
ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on April 3, 2024
March 27, 2024
Via
ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on February 7, 2024
February 01, 2024
Via
ACCESSWIRE
Why Dermata Therapeutics Stock Took Off After-Hours
↗
January 04, 2024
Dermata Therapeutics, Inc.
Via
Benzinga
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
Via
ACCESSWIRE
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
January 04, 2024
Via
ACCESSWIRE
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 20, 2023
Via
ACCESSWIRE
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
November 16, 2023
Via
ACCESSWIRE
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
November 16, 2023
Via
ACCESSWIRE
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 24, 2023
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
June 27, 2023
Via
ACCESSWIRE
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 13, 2023
Via
ACCESSWIRE
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
June 08, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 26, 2023
Via
ACCESSWIRE
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
April 20, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
March 20, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
March 16, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
